These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8522464)

  • 21. In vitro antibacterial activity of imipenem in combination with newer quinolone derivatives.
    Kern W; Gulden H; Vanek E; Kurrle E
    Chemotherapy; 1988; 34(2):117-26. PubMed ID: 3164670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The activity of four fluoroquinolones against strains of Pseudomonas aeruginosa with a different sensitivity pattern to ceftazidime and imipenem].
    Pascual A A; Joyanes P; Martínez-Martínez L; del Carmen Conejo M; Hernández G; Chaves J; Perea EJ
    Enferm Infecc Microbiol Clin; 2001 Nov; 19(9):432-4. PubMed ID: 11709121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of ciprofloxacin against resistant clinical isolates.
    Kelley SG; Bertram MA; Young LS
    J Antimicrob Chemother; 1986 Mar; 17(3):281-6. PubMed ID: 2939048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy.
    Schito GC; Sanna A; Chezzi C; Ravizzola G; Leone F; Molinari G; Menozzi MG; Pirali F
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():57-72. PubMed ID: 2681128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections.
    Huang SS; Lee SC; Lee N; See LC; Tsai MH; Shieh WB
    J Microbiol Immunol Infect; 2007 Apr; 40(2):134-40. PubMed ID: 17446961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide.
    Hoban DJ; Jones RN; Yamane N; Frei R; Trilla A; Pignatari AC
    Diagn Microbiol Infect Dis; 1993; 17(4):299-305. PubMed ID: 8112045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
    Dong SX; Wang JT; Chang SC
    J Microbiol Immunol Infect; 2012 Dec; 45(6):459-64. PubMed ID: 23102796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens.
    Bustamante CI; Drusano GL; Wharton RC; Wade JC
    Antimicrob Agents Chemother; 1987 Apr; 31(4):632-4. PubMed ID: 3111357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
    Cetinkaya E; Coban AY; Durupinar B
    Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of imipenem, third-generation cephalosporins, aztreonam and ciprofloxacin against multi-resistant gram-negative bacilli isolated from Chilean hospitals.
    Zemelman R; Bello H; Dominguez M; Gonzalez G; Mella S; Garcia A
    J Antimicrob Chemother; 1993 Sep; 32(3):413-9. PubMed ID: 8262863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
    Cafiso V; Messina C; Santagati M; Campanile F; Bonfiglio G; Stefani S
    Drugs Exp Clin Res; 2001; 27(3):107-11. PubMed ID: 11447768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibacterial properties of imipenem with special reference to the activity against methicillin-resistant staphylococci, cefotaxime-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Vurma-Rapp U; Kayser FH; Barberis-Maino L
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():27-33. PubMed ID: 3102452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between outer membrane protein profiles and resistance to ceftazidime, imipenem, and ciprofloxacin in Pseudomonas aeruginosa isolates from bacteremic patients.
    Gimeno C; Navarro D; Savall F; Millás E; Farga MA; Garau J; Cisterna R; García-de-Lomas J
    Eur J Clin Microbiol Infect Dis; 1996 Jan; 15(1):82-5. PubMed ID: 8641311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bactericidal activity and killing rate of serum against gram-positive cocci in volunteers receiving imipenem, oxacillin, vancomycin or ampicillin plus gentamicin.
    Van der Auwera P; Van Laethem Y; Klastersky J
    J Antimicrob Chemother; 1987 Aug; 20(2):239-49. PubMed ID: 3478329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro susceptibility of Staphylococcus aureus isolated from blood to currently used antistaphylococcal drugs.
    Baiocchi P; Galiè M; Santini C; Carfagna P; Cassone M; Tarasi D; Venditti M
    J Chemother; 1998 Feb; 10(1):25-8. PubMed ID: 9531072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    Bauernfeind A
    J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-vitro susceptibility of Haemophilus influenzae to meropenem compared with imipenem, five other beta-lactams, chloramphenicol and ciprofloxacin.
    Powell M; Seetulsingh P; Williams JD
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():175-81. PubMed ID: 2808206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection of oxacillin resistance in oxacillin-sensitive Staphylococcus aureus through exposure to ciprofloxacin but not piperacillin/tazobactam.
    Evans ME
    Eur J Clin Microbiol Infect Dis; 2002 Aug; 21(8):621-3. PubMed ID: 12226696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Canadian Pseudomonas aeruginosa susceptibility study from 48 medical centers: focus on ciprofloxacin.
    Blondeau JM; Suter ME; Borsos S; Misfeldt C
    Int J Antimicrob Agents; 1998 Nov; 10(4):297-302. PubMed ID: 9916904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.